Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

143.18 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High? ↗

September 12, 2023

The company is working on a treatment for a disorder than can cause children to begin puberty early.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 08, 2023

Via Benzinga

FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning ↗

August 21, 2023

The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated

Via Benzinga

Analyst Ratings for Neurocrine Biosciences ↗

August 21, 2023

Via Benzinga

Analyst Ratings for Neurocrine Biosciences ↗

August 02, 2023

Via Benzinga

Earnings Outlook For Neurocrine Biosciences ↗

July 31, 2023

Via Benzinga

What To Know About BMO Capital's Upgrade of Neurocrine Biosciences ↗

July 06, 2023

Via Benzinga

Expert Ratings for Neurocrine Biosciences ↗

June 30, 2023

Via Benzinga

What 15 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

June 05, 2023

Via Benzinga

Confidence Boost From Ingrezza Sales: Analyst Upgrades Neurocrine Biosciences ↗

July 06, 2023

BMO Capital Markets has upgraded Neurocrine Biosciences Inc (NASDAQ: NBIX) from Underperform to Market Perform, with a price target of $96,

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023 ↗

July 06, 2023

Via Benzinga

Neurocrine Biosciences's Return On Capital Employed Overview ↗

May 08, 2023

Via Benzinga

Neurocrine Biosciences Clocks 35% Revenue Growth In Q1, Misses On Bottom-Line Performance ↗

May 03, 2023

Via Benzinga

Neurocrine Biosciences: Q1 Earnings Insights ↗

May 03, 2023

Via Benzinga

Neurocrine Biosciences's Earnings: A Preview ↗

May 02, 2023

Via Benzinga

What 15 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

April 17, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗

May 04, 2023

Via Benzinga

3 Pharma Stocks That Could See a Surge in Demand in 2023 ↗

April 24, 2023

These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead

Via InvestorPlace

Expert Ratings for Neurocrine Biosciences ↗

March 30, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 ↗

March 30, 2023

Via Benzinga

Analyst Expectations for Neurocrine Biosciences's Future ↗

March 03, 2023

Via Benzinga

3 Growth Stocks That Could Disrupt the Healthcare Industry ↗

March 13, 2023

These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023 ↗

March 03, 2023

Via Benzinga

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

February 14, 2023

From Sentia Medical Sciences, Inc.

Via GlobeNewswire

Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets ↗

February 06, 2023

Neurocrine also topped fourth-quarter revenue expectations on Monday.

Via Investor's Business Daily

Neurocrine Biosciences Earnings Preview ↗

February 03, 2023

Via Benzinga

Earnings Scheduled For February 6, 2023 ↗

February 06, 2023

Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion.

Via Benzinga

Five Best And Worst Performing Healthcare Stocks In January 2023 ↗

February 05, 2023

After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗

February 03, 2023

Via Benzinga

Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing' ↗

February 03, 2023

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.